OSE Immunotherapeutics Regains Control of ABBV-230 Early Development in Strategic Partnership Amendment with AbbVie
核心洞察
OSE Immunotherapeutics announced a strategic amendment to its AbbVie (搜索) partnership, regaining control of ABBV-230's preclinical and Phase 1 development while AbbVie retains rights for later-stage development and commercialization.
ABBV-230 is a monoclonal antibody targeting ChemR23 (搜索), a dual-function receptor involved in inflammation initiation and resolution, representing a potential first-in-class therapy for chronic inflammatory diseases.
The restructured agreement maintains unchanged commercial terms including royalties and milestone payments, with OSE assuming full financial responsibility for early-stage development contingent on securing adequate funding.
OSE Immunotherapeutics SA announced a strategic amendment to its partnership agreement with AbbVie (搜索) regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammation currently in preclinical development. The revised agreement, announced December 8, 2025, shifts early-stage development responsibilities back to OSE while preserving AbbVie's long-term commercialization rights.
Partnership Restructuring Details
Under the amended agreement, OSE Immunotherapeutics regains control of ABBV-230's preclinical and Phase 1 development, drawing on its deep immunology expertise. The company will assume full financial responsibility for these early development activities, contingent upon securing adequate funding at its sole discretion.
AbbVie (搜索) maintains its position as the exclusive licensee and retains rights to control future development and commercialization following successful completion of Phase 1. This structure aligns development responsibilities with each company's core strengths while preserving both parties' continued enthusiasm for ABBV-230's therapeutic potential.
Commercial Terms and Milestone Adjustments
All existing commercialization rights remain unchanged under the restructured partnership, including royalties on global net sales and sales-based milestone payments. OSE Immunotherapeutics retains its full economic entitlements under the original agreement established in February 2024.
The amendment includes one significant milestone payment adjustment: OSE will no longer receive the previously anticipated milestone payment tied to Phase 1 clinical study initiation. However, the company becomes eligible for milestone payments in subsequent development stages should AbbVie (搜索) advance the candidate beyond Phase 1.
ChemR23 Target and Therapeutic Potential
ABBV-230 targets ChemR23 (搜索), a dual-function receptor involved in both the initiation and resolution of inflammation, depending on the ligand that binds to it. The receptor plays a key role in multiple diseases by regulating immune cell recruitment and activity. Both companies remain committed to exploring its potential as a first-in-class therapy for inflammation resolution.
Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, commented: "The overall value of our collaboration with AbbVie (搜索) for ABBV-230 remains unchanged. Assuming leadership of early-stage development enables OSE to accelerate progress on this innovative program while leveraging our core immunology expertise. The restructured agreement reflects the value we've built and our shared commitment to advancing transformative therapies for chronic inflammatory diseases."
Company Background
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation that address unmet patient needs. The company partners with leading academic institutions and biopharmaceutical companies to develop and bring transformative medicines to market for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext.